NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United States. Food and Drug Administration. Remove constraint Subjects: United States. Food and Drug Administration.

Search Results

122. Systemic antibacterial and antifungal drugs: susceptibility test interpretive criteria labeling for NDAs and ANDAs

123. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system

124. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

125. Unique device identification: policy regarding compliance dates for class I and unclassified devices : immediately in effect guidance for industry and Food and Drug Administration staff

126. Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act

130. Requirements for transactions with first responders under section 582 of the Federal Food, Drug, and Cosmetic Act--compliance policy